secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioXcel Therapeutics, Inc. (BTAI)
CIK:        0001720893
Form:       8-K
Filed at:   2023-06-30T23:59:59+00:00
Accession:  0001104659-23-077126
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

BioXcel shareholders elect three Class II directors, ratify Ernst & Young as auditor
--------------------------------------------------------------------------------

- Elected directors: Sandeep Laumas (12,360,360 for, 8,899,824 withheld), Michael Miller (21,149,269 for, 110,915 withheld), Michal Votruba (18,041,794 for, 3,218,390 withheld).
- Ratified Ernst & Young as auditor for FY2023 with 24,849,840 for, 51,173 against, 7,597 abstained.
- Turnout was 24,908,610 shares (85.42% of outstanding) as of April 27, 2023 record date.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720893/000110465923077126/0001104659-23-077126-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720893/000110465923077126/tm2320221d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-077126

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer